Tien Liang BioTech Co., Ltd. (4127) fair value: what the stock is really worth
As of Nov 3, 2026: fair value (intrinsic value) of Tien Liang BioTech Co., Ltd. stock TWD 6.93, price TWD 33.70, that is 79.4% below the price, quality 39 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 30, 2026.
How to read this chart
60‑month range 10.25 TWD – 92.30 TWD · fair‑value band 5.17 TWD – 10.34 TWD · the 33.70 TWD price screens above the 6.93 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 30, 2026.
Follow Tien Liang BioTech Co. in your weekly email
Every Wednesday you see whether Tien Liang BioTech Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Tien Liang BioTech Co., Ltd. manufactures and sells pharmaceutical products in Taiwan. The company offers Chinese and Western medicine, other healthcare, and cosmetic products through online and offline channels.
Show moreShow less
Tien Liang BioTech Co., Ltd. was founded in 1971 and is based in New Taipei City, Taiwan.
Stock analysis
Tien Liang BioTech Co., Ltd. (4127) currently trades at 33.70 TWD, while our model-based Fair Value estimate is 6.93 TWD, 79.4% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.
Scenario range: 5.17 TWD (bear) to 10.34 TWD (bull), the price of 33.70 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Tien Liang BioTech Co., Ltd. reported revenue of 512M TWD in FY2025 versus 571M TWD in FY2021, a compound −2.7%/yr. Reported net income was −10.3M TWD in FY2025.
Key figures
Market cap 1.5B TWD (≈ $47.0M) Micro · P/E ratio 22.2 · P/S ratio 2.37 · EPS (TTM) 1.52 TWD · Dividend yield 1.4% · Net margin 10.6% · Return on equity 14.3% · Return on assets (EBIT) 3.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).
What moves the price
The share trades about 63% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −79%, 4127 screens richer than that median.
Fair Value models
Bear5.17 TWDFair Value 6.93 TWDBull10.34 TWD
Price 33.70 TWD · Downside -79.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.28 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.43/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+32.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.5%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10.8% (2020) → −3.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Tien Liang BioTech Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 554 stocks
Beats the industry median on 3/12 measures
Overall it trails its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside−79.4% · Bottom 25%
Profitability
Return on equity (12 months)14.3% · Top 25%
Return on assets−0.9% · Bottom 25%
Net margin (12 months)10.6% · Above median
Operating margin (12 months)5.3% · Below median
Growth and dividend
Revenue growth (quarter YoY)45.1% · Top 25%
Dividend yield (12 months)1.4% · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)22.2× · Pricier than median
P/B3.25× · Priciest 25%
P/S (12 months)2.37× · Pricier than median
EV/EBITDA85.8× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)100· sector 26
PAST (return on equity)57· sector 29
HEALTH (low debt)0· sector 96
DIVIDEND (yield)29· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Tien Liang BioTech Co., Ltd. (4127) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of 6.93 TWD versus a price of 33.70 TWD, about 79% lower (overvalued).
What is the fair value of 4127?
Our model-based fair value for Tien Liang BioTech Co., Ltd. is 6.93 TWD (as of Oct 30, 2026), built from audited fundamentals. The current price: 33.70 TWD.
What is the quality score of 4127?
Tien Liang BioTech Co., Ltd. has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tien Liang BioTech Co., Ltd. (4127)?
Our model-based price target is the fair value of 6.93 TWD (as of Oct 30, 2026) from 1 valuation models. Cautious scenario 5.17 TWD, optimistic scenario 10.34 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Tien Liang BioTech Co., Ltd. stock forecast for 2026?
Our models put fair value at 6.93 TWD, about 79% lower versus a price of 33.70 TWD (overvalued). Cautious scenario 5.17 TWD, optimistic scenario 10.34 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Tien Liang BioTech Co., Ltd. (4127)?
Tien Liang BioTech Co., Ltd. reported trailing-twelve-month revenue of about 651M TWD (latest available figure, as of Oct 30, 2026).
Does Tien Liang BioTech Co., Ltd. pay a dividend?
Tien Liang BioTech Co., Ltd. currently shows a dividend yield of 1.43% relative to its recent price (as of Oct 30, 2026).
What is the intrinsic value of Tien Liang BioTech Co., Ltd. (4127)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tien Liang BioTech Co., Ltd. it is 6.93 TWD per share (as of Oct 30, 2026), against a price of 33.70 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Tien Liang BioTech Co., Ltd. stock overvalued or undervalued in 2026?
As of Oct 30, 2026, 4127 trades above its calculated fair value: price 33.70 TWD, fair value 6.93 TWD, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4127?
No. The price is what the market pays today (33.70 TWD); the fair value is what the company's own numbers justify (6.93 TWD). For Tien Liang BioTech Co., Ltd. the two are 26.77 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Tien Liang BioTech Co., Ltd. worth?
The market values Tien Liang BioTech Co., Ltd. at about 1.5B TWD (market capitalisation, as of Oct 30, 2026). Per share that is 33.70 TWD; our models calculate a fair value of 6.93 TWD per share.
What do the bullish and bearish scenarios say about 4127?
Our models span a range for Tien Liang BioTech Co., Ltd.: cautious scenario 5.17 TWD, base 6.93 TWD, optimistic 10.34 TWD per share (as of Oct 30, 2026, price 33.70 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4127?
Tien Liang BioTech Co., Ltd. trades at a price-to-earnings ratio of 22.2 (as of Oct 30, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 6.93 TWD is built from several models across several years. Other multiples: P/B 3.3, P/S 2.4, EV/EBITDA 85.8.
How solid is the balance sheet of Tien Liang BioTech Co., Ltd. (4127)?
Balance-sheet figures for Tien Liang BioTech Co., Ltd. (as of Oct 30, 2026): return on equity 14.3%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 4127 from its 52-week high?
Tien Liang BioTech Co., Ltd. trades at 33.70 TWD, about 63% below its 52-week high of 92.30 TWD and 14% above the low of 29.50 TWD (as of Nov 3, 2026). Distance from the high says nothing about value: that is what the fair value of 6.93 TWD is for.
Which stocks are comparable to Tien Liang BioTech Co., Ltd.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Jiangsu Hengrui Pharmaceuticals Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tien Liang BioTech Co., Ltd. stock attractive at the current price?
The data as of Oct 30, 2026: price 33.70 TWD, calculated fair value 6.93 TWD (−79%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4127 calculated?
We run Tien Liang BioTech Co., Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 6.93 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Tien Liang BioTech Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tien Liang BioTech Co., Ltd. (4127)?
The closing price on Nov 3, 2026 was 33.70 TWD. Our model-based fair value is 6.93 TWD, about 79% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tien Liang BioTech Co., Ltd. right now?
The price sits above even our optimistic bull case (10.34 TWD). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (5.17 TWD to 10.34 TWD) leaves room in how you read the outcome.
Key figures of Tien Liang BioTech Co., Ltd.
How large is the market capitalisation of Tien Liang BioTech Co., Ltd. (4127)?
The market capitalisation of Tien Liang BioTech Co., Ltd. is 1.5B TWD (≈ $47.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tien Liang BioTech Co., Ltd. (4127)?
The price-to-sales ratio of Tien Liang BioTech Co., Ltd. is 2.37 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tien Liang BioTech Co., Ltd. (4127)?
Earnings per share at Tien Liang BioTech Co., Ltd. are 1.52 TWD (price ÷ EPS = P/E 22.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Tien Liang BioTech Co., Ltd. (4127)?
The dividend yield of Tien Liang BioTech Co., Ltd. is 1.4% (payout 31.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Tien Liang BioTech Co., Ltd. (4127)?
The net margin of Tien Liang BioTech Co., Ltd. is 10.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tien Liang BioTech Co., Ltd. (4127)?
The return on equity (ROE) of Tien Liang BioTech Co., Ltd. is 14.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tien Liang BioTech Co., Ltd. (4127)?
On an EBIT basis the return on assets of Tien Liang BioTech Co., Ltd. is 3.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tien Liang BioTech Co., Ltd. (4127)?
The operating margin of Tien Liang BioTech Co., Ltd. is 5.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tien Liang BioTech Co., Ltd. (4127)?
Revenue at Tien Liang BioTech Co., Ltd. is growing +45.1% versus a year earlier (3y avg −1.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tien Liang BioTech Co., Ltd. (4127)?
Earnings per share at Tien Liang BioTech Co., Ltd. are growing +94.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Tien Liang BioTech Co., Ltd. (4127) generate?
The free cash flow of Tien Liang BioTech Co., Ltd. is −4.1M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Tien Liang BioTech Co., Ltd. (4127) carry?
The net debt of Tien Liang BioTech Co., Ltd. is 476M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Tien Liang BioTech Co., Ltd. in the live analysis
One click puts Tien Liang BioTech Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Oct 30, 2026